Table 2 Risk of key outcomes based on disease site involvement at last assessment before CAR-T therapy.

From: CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma

Sites1

Not achieving a CR2

PFS3

OS3

Infradiaphragmatic nodes

OR 2.13 (1.18–3.91, p = 0.013)

HR 1.32 (0.92–1.90, p = 0.13)

HR 1.44 (0.94–2.21, p = 0.092)

Spleen

NA4

NA4

HR 0.62 (0.27–1.42, p = 0.3)

CNS/cranial sinuses/orbital

NA4

HR 1.80 (1.06–3.08, p 0.031)

HR 1.85 (1.05–3.26, p < 0.034)

Lungs/pleura/pericardium

OR 2.34 (1.14–64.87, p = 0.021)

NA4

NA4

Gastrointestinal/peritoneum

OR 1.88 (0.96–3.73, p = 0.067)

HR 1.34 (0.91–2, p = 0.14)

HR 1.62 (1.03–2.55, p = 0.037)

Adrenal/genitourinary

OR 2.61 (1.09–6.53, p = 0.033)

HR 3.35 (2.16–5.19, p < 0.001)

HR 2.59 (1.58–4.23, p < 0.001)

Hepatobiliary/pancreas

OR 2.04 (0.76–5.74, p = 0.2)

HR 1.63 (1.01–2.63, p = 0.047)

HR 1.99 (1.19–3.33, p < 0.009)

Bone/soft tissue

NA4

HR 1.03 (0.71–1.50, p = 0.9)

NA4

  1. For each site, the reference for comparison is non-involvement of the same site at the last assessment before CAR-T. The reference group for all comparisons is no involved in the specified site. 1. Sites were selected based on association with the outcome in univariable regression models. Models presented in table are multivariable adjusted for age, LBCL transformation, pre-lymphodepletion LDH, bridging, and CAR-T product. 2. Logistic regression model. 3. Cox-regression. 4. Multivariable regression models are performed if there was a significant association (p < 0.05) in univariable regression.
Back to article page